Department of Surgery II, Faculty of Medicine, University of Miyazaki, Kihara 5200, Kiyotake, Miyazaki, 889-1692, Japan.
Anticancer Res. 2010 Jul;30(7):3099-102.
Prognostic impact of tumour marker index (TMI) based on preoperative serum carcinoembryonic antigen (CEA) and CYFRA 21-1 in non-small cell lung cancer (NSCLC) was examined using patients with a follow-up period more than 5 years.
Two hundred and ninety-three consecutive NSCLC patients were reviewed retrospectively, and any patients with follow-up periods less than 5 years were omitted.
The 5-year survival of the patients with normal and high serum CEA levels was 71.52% and 48.41%, respectively (p<0.0001). The 5-year survival of the patients with a high serum CYFRA 21-1 level was 39.66%, which was significantly poorer compared with that of the patients with a normal serum CYFRA 21-1 level (66.95%, p<0.0001). There was a 5-year-survival rate of 72.28% in patients with a TMI less than or equal to 1.0 compared to only 37.08% in patients with a TMI greater than 1.0 (p<0.0001). Both univariate and multivariate analyses indicated the independent prognostic impact of TMI.
TMI may be useful for predicting the prognosis of NSCLC patients.
使用随访时间超过 5 年的患者，检查了基于术前血清癌胚抗原（CEA）和细胞角蛋白 19 片段（CYFRA 21-1）的肿瘤标志物指数（TMI）对非小细胞肺癌（NSCLC）的预后影响。
回顾性分析了 293 例连续 NSCLC 患者，排除了随访时间少于 5 年的任何患者。
CEA 水平正常和升高的患者 5 年生存率分别为 71.52%和 48.41%（p<0.0001）。血清 CYFRA 21-1 水平升高的患者 5 年生存率为 39.66%，明显低于血清 CYFRA 21-1 水平正常的患者（66.95%，p<0.0001）。TMI 小于或等于 1.0 的患者 5 年生存率为 72.28%，而 TMI 大于 1.0 的患者仅为 37.08%（p<0.0001）。单因素和多因素分析均表明 TMI 具有独立的预后影响。
TMI 可能有助于预测 NSCLC 患者的预后。
